Several biopharma companies are implementing significant layoffs as part of restructuring efforts to extend their cash runways. Ovid, Lexicon Pharmaceuticals, Acelyrin, and FibroGen are among those reducing their workforce, with layoffs ranging from 33% to 75% of their staff. These moves follow disappointing clinical trial results and strategic shifts in focus, aiming to optimize resources and ensure continued funding for research and development.